logo
BMI is B-A-D, a new study suggests. Here's a better way to measure weight

BMI is B-A-D, a new study suggests. Here's a better way to measure weight

CTV News24-06-2025
While waist circumference is a better tool than BMI, it's not as accurate as bioelectrical impedance analysis. Ralf Geithe/iStockphoto/Getty Images via CNN Newsource
When it comes to measuring weight, BMI is the acronym everyone loves to hate. Health professionals have long used body mass index as a quick screening tool to fast-track certain patients into a 'code red' management plan — people whose weight puts them in danger of future health problems.
The issue is that BMI measures health risk by calculating height and weight. However, muscle and bone weigh more than fat, so BMI measurements can overestimate the danger for people with a muscular build or a larger frame. Conversely, BMI can underestimate health concerns in older adults and anyone who has lost muscle, according to the Harvard T.H. Chan School of Public Health in Boston.
Now, authors of a new study say a different approach to weight measurement may be a more accurate way to predict future health issues. Bioelectrical impedance analysis, or BIA, uses undetectable electric currents to measure not only the percentage of body fat but also lean muscle mass and water weight.
The technology works like this: You stand on metal plates on the machine while holding your hands or thumbs on another metal attachment held away from the body. Once started, the machine sends a weak electrical current through the body. Body fat, muscle and bone all have different electrical conductivity, so the machine uses algorithms to determine lean muscle mass, body fat percentage and water weight.
'We found body-fat percentage to be a stronger predictor of 15-year mortality risk in adults between the ages of 20 and 49 than BMI,' said Arch Mainous III, lead author of the study published Tuesday in the journal Annals of Family Medicine.
When it came to deaths from heart disease, people with high body fat as measured by BIA were 262% times more likely to die than people who had a healthy percentage of body fat, said Mainous, a professor and vice chair of research in community health and family medicine at the University of Florida School of Medicine.
'Now remember, using BMI did not flag any risk at all in this younger population, which isn't one we typically consider to be at high risk for heart disease,' said senior author Dr. Frank Orlando, a clinical associate professor of community health and family medicine at University of Florida Health.
'Think of the interventions we can do to keep them healthy when we know this early. I think it's a game-changer for how we should look at body composition,' Orlando said.
The problem with BMI
BMI is measured by dividing your weight by the square of your height. (If you are mathematically challenged like I am, the National Institutes of Health has a free calculator.)
In BMI world, a body mass between 18.5 and 24.9 is a healthy weight, between 25 and 29.9 is overweight, between 30 and 34.9 is obese, between 35 and 39.9 is class 2 obesity, and anything greater than 40 is 'severe' or class 3 obesity. People are considered underweight if their BMI is lower than 18.5.
Using BMI to measure health risk works — on a population level. Countless studies have shown that a greater BMI really does correlate with developing chronic diseases of all kinds — cancer, heart disease, type 2 diabetes, kidney and liver disease, and more.
Where BMI fails is at the patient level. Imagine a patient who is 'skinny fat' — thin on the outside but riddled with globs of fat wrapped around major organs on the inside. Your BMI would be fine even though your health was at risk.
'Those people are more likely to have nonalcoholic fatty liver disease, more likely to have elevated glucose, more likely to have elevated blood pressure, and more likely to have inflammation in general,' Mainous said.
All of these health issues can be treated, stopped and in some cases even reversed if caught early enough, he added.
While doctors are aware of the issues with BMI, many prefer it 'because it is cheap and easily put into practice,' Mainous said. 'They'd like to use a more direct measurement such as a DEXA scan, but those cost too much and are not widely available, so everyone falls back to the indirect measure of BMI.'
DEXA stands for dual-energy X-ray absorptiometry and is the gold standard for body mass analysis. Such machines can cost between US$45,000 and $80,000, so patients typically travel to a hospital or specialty center to get the scan, Orlando said. The cost to the patient can easily be $400 to $500 per scan, he said.
'However, we found the newer versions of bioelectrical impedance are pretty accurate, giving some valid and reliable results,' Orlando said.
One note — at-home based bioelectrical impedance products are not nearly as accurate, said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver.
'They can be affected a lot by how much body fluid you have, how hydrated you are,' said Freeman, who was not involved with the new research. 'At-home measurements will only give a ballpark — the clinic-based machines are more precise.'
Is it time for doctors to embrace body fat measurements?
The new study analyzed data on 4,252 men and women who participated in the 1999 to 2004 federal survey called NHANES, or the National Health and Nutrition Examination Survey, a yearly checkup of the nation's health.
Technicians measured each person's body composition, including height, weight and waist circumference. In addition, all participants underwent a clinic-based bioelectrical impedance analysis, which measures the body's resistance to electrical currents.
Researchers then compared that data with the National Death Index through 2019 to see how many people died. After adjusting for age, race and poverty status, the study found a BMI that labeled someone as obese was not associated with a statistically significant higher risk of death from any cause, when compared with those in healthy BMI range.
People with high body fat as measured by bioimpedance analysis, however, were 78% more likely to die from any cause, Mainous said. Measuring waist circumference was also helpful, but not as accurate as body mass.
Add that to the 262% higher chance of dying from heart disease found by the study, and it's a no-brainer for doctors to use bioelectrical impedance analysis on patients, Orlando said.
'Let's face it, the magnitude of risk this study shows is enormous,' Freeman said. 'It's scary to think that we may have been using a surrogate — BMI — that may not have been all that accurate over the years.'
The study shows how better weight measurements could easily become personalized medicine, Freeman added.
'Imagine you came into your doctor's office,' he said. 'They provided your body fat percentage and an individualized risk assessment. They talked to you about exercise and other lifestyle changes and referred you to a nutritionist.
'They gave you an opportunity to make these changes, and then if needed, helped you out with medication. If the medical profession did this and were able to save many more lives, that would be amazing.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value
Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value

National Post

time2 hours ago

  • National Post

Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value

Article content SALT LAKE CITY — Echo, the global leader in hydrogen health technology, is responding forcefully to a wave of misinformation being spread by influencers with financial agendas. False claims that the Echo Flask causes heavy metals poisoning or stops working after six months are not only wrong—they're dangerous. Article content 'Hydrogen health is growing fast—and that growth has attracted a swarm of pseudo-scientific influencers using fear, not facts, to push products that pay them more money,' said Josh Carr, CEO of Echo. 'We're done letting those lies go unchallenged.' Article content At the center of the recent smear campaign are false allegations that Echo's hydrogen water bottle stops producing hydrogen after six months and may leach harmful metals. These claims are categorically false, unsupported by any lab data, and contradicted by third-party testing and thousands of happy customers. Article content The Echo Flask is engineered with platinum-coated electrodes, a proprietary proton exchange membrane, and a self-cleaning system—guaranteeing high-concentration hydrogen performance for over 10,000 uses. Echo backs every unit with a 5-year warranty and provides published test results verifying both hydrogen output and water purity. Article content 'These accusations aren't coming from scientists or doctors. They're coming from influencers who make more money when they scare people into buying hydrogen tablets,' Carr said. 'They claim our bottle causes 'heavy metals poisoning,' but produce no lab report, no data—just fear bait.' Article content Echo acknowledges that some low-end hydrogen bottles do degrade quickly—especially those built with cheap electrodes or mass-produced knockoff parts. But the Echo Flask is in a different class: medical-grade materials, clean hydrogen output, and durable construction backed by a decade of engineering. Article content In contrast, hydrogen tablets—often promoted as a better alternative—have major safety, quality, and cost issues. Many contain unregulated magnesium, along with heavy metals like lead, and begin to degrade rapidly the moment you open the package. Article content 'These tablet pushers mislead the public with confusing numbers and manipulated science,' Carr continued. 'They talk about 'high ppm levels' as if that means something useful—but hydrogen dosage is measured in milligrams, not parts per million. A high ppm in a tiny volume can mean a low actual dose. Consumers are literally paying more for less. It's dirty, expensive water with barely any usable hydrogen.' Article content Beyond misleading metrics, tablets are a recurring cost—often over $150/month to match the hydrogen levels the Echo Flask delivers for pennies per day. They're unstable, expensive, and fundamentally misrepresented. Article content 'We've tested these tablets. We've tested our bottles. We publish our data. And we stand behind our technology. That's the difference,' said Carr. 'People deserve truth—not hype.' Article content As the hydrogen wellness category continues to grow, Echo urges consumers to look past influencer theatrics and focus on science, transparency, and value. For third-party test results, hydrogen education, and Echo's full product lineup, visit Article content Article content Article content Article content

UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025
UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025

CTV News

time2 hours ago

  • CTV News

UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025

The logo for UnitedHealth Group appears above a trading post on the floor of the New York Stock Exchange, April 17, 2025. (AP Photo/Richard Drew, file) UnitedHealth delivered disappointing second-quarter earnings and went conservative with its 2025 forecast as soaring medical costs continue to swamp insurers. The health care giant said Tuesday expenses that have jumped beyond what it expected when it set coverage prices will continue to pressure its performance. But the company expects a return to earnings growth in 2026. UnitedHealth now expects adjusted earnings of at least $16 per share in 2025 after withdrawing its previous forecast in May. It had started 2025 with expectations of making up to $30 per share. For the full year, analysts forecast earnings of $20.64 per share, according to the data firm FactSet. UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. The Eden Prairie, Minnesota, company also operates a growing Optum business that provides care and technology support. In May, the company withdrew its 2025 forecast due to higher-than-expected medical costs, and CEO Andrew Witty departed the company abruptly. He was replaced by Chairman Stephen Hemsley, who was the UnitedHealth CEO for more than a decade until 2017. That came after the company took the rare step in April of cutting its forecast. That pushed UnitedHealth shares down $130 in its worst single-day performance in over 25 years. Hemsley promised in June that UnitedHealth would establish a 'prudent' 2025 earnings outlook when it detailed second-quarter results. He also said the company had underestimated care activity and cost trends, but improvements were being made. In the second quarter, UnitedHealth reported adjusted earnings of $4.08 per share on $111.6 billion in total revenue. Analysts expected earnings of $4.48 per share on $111.5 billion in revenue, according to FactSet. The company's profit fell 19% to $3.41 billion even as revenue rose 13%. Medical costs, the company's biggest operating expense, jumped 20% to $78.6 billion in the quarter. UnitedHealth is normally the first insurer to report earnings every quarter. But this summer, it followed competitors like Elevance Health Inc. and Centene Corp. that have lowered their annual forecasts and delivered disappointing results. Several insurers say they have been hit by medical costs that are growing faster than expected. Companies have seen a rise in expensive emergency rooms visits and growing prescription drug costs, especially from expensive cancer treatments and gene therapy. They've also seen a rise in behavioral health care, which includes the treatment of mental health conditions and substance use disorders. UnitedHealth shares slid about more than 3% to $272.30 before the opening bell Tuesday. That price topped $630 last November to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. Shares are down 44% so far this year. The Dow Jones Industrial Average, of which UnitedHealth is a member, has climbed 5%. Tom Murphy, The Associated Press

Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL
Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL

Globe and Mail

time2 hours ago

  • Globe and Mail

Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL

(LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 study titled 'A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)'. The study aims to evaluate the efficacy and safety of the experimental drug Pirtobrutinib compared to the standard treatment of Bendamustine plus Rituximab in patients who have not received prior treatment for CLL/SLL. The study tests two interventions: Pirtobrutinib, an oral medication, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its potential to offer a more effective and safer treatment option. This interventional study is randomized with a parallel assignment model. Participants are divided equally into two groups, with no masking involved. The primary purpose is treatment, allowing crossover for patients with disease progression. The study began on September 23, 2021, with an active but not recruiting status. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial for tracking the study's development and anticipated results. The outcome of this study could significantly impact Eli Lilly's and Loxo Oncology's stock performance by potentially introducing a new treatment option in the CLL/SLL market. This could influence investor sentiment positively, especially if Pirtobrutinib proves to be a superior treatment. Competitors in the oncology space will be closely monitoring these developments. The study remains active, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store